Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function

Neuropharmacology

Volumn 99, Issue , 2015, Pages 715-725

  El Hage, Cynthia ^a   Bédard, Anne Marie ^a   Samaha, Anne Noël ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Amphetamine; Dopamine supersensitivity; Haloperidol; Olanzapine; Schizophrenia

Indexed keywords

AMPHETAMINE; DOPAMINE; HALOPERIDOL; OLANZAPINE; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRD2 PROTEIN, RAT; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DYSFUNCTION; CAUDATE NUCLEUS; CONDITIONED REWARD; CONTROLLED STUDY; CORPUS STRIATUM; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN; RAT; REWARD; SUPERSENSITIVITY; AGONISTS; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; INSTRUMENTAL CONDITIONING; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CONDITIONING, OPERANT; DOPAMINE; DOPAMINE AGONISTS; DRUG RESISTANCE; GABA AGONISTS; HALOPERIDOL; MALE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA; REWARD;

EID: 84944716023     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.03.012     Document Type: Article

References (61)

1. H. Asper, M. Baggiolini, H.R. Burki, H. Lauener, W. Ruch, and G. Stille Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol Eur. J. Pharmacol. 22 1973 287 294
2. A.M. Bedard, J. Maheux, D. Levesque, and A.N. Samaha Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues Neuropsychopharmacology 36 2011 1248 1259
3. A.M. Bedard, J. Maheux, D. Levesque, and A.N. Samaha Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia Schizophr. Bull. 39 2013 692 702
4. D.R. Burt, I. Creese, and S.H. Snyder Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain Science 196 1977 326 328
5. M. Cador, J.R. Taylor, and T.W. Robbins Potentiation of the effects of reward-related stimuli by dopaminergic-dependent mechanisms in the nucleus accumbens Psychopharmacology (Berl) 104 1991 377 385
6. G.D. Carr, and N.M. White Conditioned place preference from intra-accumbens but not intra-caudate amphetamine injections Life Sci. 33 1983 2551 2557
7. D.E. Casey Tardive dyskinesia E. Borroni, J. K. D., Psychopharmacology: the Fourth Generation of Progress 1995 Raven Press Ltd New York 1497 1501
8. G. Chouinard, B.D. Jones, and L. Annable Neuroleptic-induced supersensitivity psychosis Am. J. Psychiatry 135 1978 1409 1410
9. G.G. Dougherty Jr., and E.H. Ellinwood Jr. Chronic D-amphetamine in nucleus accumbens: lack of tolerance or reverse tolerance of locomotor activity Life Sci. 28 1981 2295 2298
10. L. Farde, A.L. Nordstrom, F.A. Wiesel, S. Pauli, C. Halldin, and G. Sedvall Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch. Gen. Psychiatry 49 1992 538 544
11. L. Farde, F.A. Wiesel, C. Halldin, and G. Sedvall Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs Arch. Gen. Psychiatry 45 1988 71 76
12. L. Farde, F.A. Wiesel, A.L. Nordstrom, and G. Sedvall D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics Psychopharmacology (Berl) 99 Suppl. l 1989 S28 S31
13. L.W. Fitzgerald, A.Y. Deutch, G. Gasic, S.F. Heinemann, and E.J. Nestler Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs J. Neurosci. 15 1995 2453 2461
14. P.J. Fletcher Effects of d-fenfluramine and metergoline on responding for conditioned reward and the response potentiating effect of nucleus accumbens d-amphetamine Psychopharmacology (Berl) 118 1995 155 163
15. S.B. Floresco, R.J. McLaughlin, and D.M. Haluk Opposing roles for the nucleus accumbens core and shell in cue-induced reinstatement of food-seeking behavior Neuroscience 154 2008 877 884
16. K.M. Gill, J.M. Cook, M.M. Poe, and A.A. Grace Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia Schizophr. Bull. 40 2014 341 350
17. N. Ginovart, A.A. Wilson, D. Hussey, S. Houle, and S. Kapur D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats Neuropsychopharmacology 34 2009 662 671
18. W.M. Glazer Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality J. Clin. Psychiatry 61 Suppl. 3 2000 16 21
19. A. Graff-Guerrero, R. Mizrahi, O. Agid, H. Marcon, P. Barsoum, P. Rusjan, A.A. Wilson, R. Zipursky, and S. Kapur The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study Neuropsychopharmacology 34 2009 1078 1086
20. C.J. Harmer, P.K. Hitchcott, S.L. Morutto, and G.D. Phillips Repeated d-amphetamine enhances stimulated mesoamygdaloid dopamine transmission Psychopharmacology (Berl) 132 1997 247 254
21. G. Juckel, F. Schlagenhauf, M. Koslowski, D. Filonov, T. Wustenberg, A. Villringer, B. Knutson, T. Kienast, J. Gallinat, J. Wrase, and A. Heinz Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics Psychopharmacology (Berl) 187 2006 222 228
22. S. Kapur, S.C. Barsoum, and P. Seeman Dopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQ Neuropsychopharmacology 23 2000 595 598
23. S. Kapur, and G. Remington Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient Biol. Psychiatry 50 2001 873 883
24. S. Kapur, S.C. VanderSpek, B.A. Brownlee, and J.N. Nobrega Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy J. Pharmacol. Exp. Ther. 305 2003 625 631
25. A.E. Kelley, and J.M. Delfs Dopamine and conditioned reinforcement. I. Differential effects of amphetamine microinjections into striatal subregions Psychopharmacology (Berl) 103 1991 187 196
26. A.E. Kelley, A.M. Gauthier, and C.G. Lang Amphetamine microinjections into distinct striatal subregions cause dissociable effects on motor and ingestive behavior Behav. Brain Res. 35 1989 27 39
27. P.H. Kelly, and S.D. Iversen Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats Eur. J. Pharmacol. 40 1976 45 56
28. P. Kirsch, S. Ronshausen, D. Mier, and B. Gallhofer The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients Pharmacopsychiatry 40 2007 196 198
29. C.C. Ledford, R.A. Fuchs, and R.E. See Potentiated reinstatement of cocaine-seeking behavior following D-amphetamine infusion into the basolateral amygdala Neuropsychopharmacology 28 2003 1721 1729
30. J.A. Lieberman, T.S. Stroup, J.P. McEvoy, M.S. Swartz, R.A. Rosenheck, D.O. Perkins, R.S. Keefe, S.M. Davis, C.E. Davis, B.D. Lebowitz, J. Severe, J.K. Hsiao Clinical Antipsychotic Trials of Intervention Effectiveness, I Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N. Engl. J. Med. 353 2005 1209 1223
31. A. Louilot, H. Simon, K. Taghzouti, and M. Le Moal Modulation of dopaminergic activity in the nucleus accumbens following facilitation or blockade of the dopaminergic transmission in the amygdala: a study by in vivo differential pulse voltammetry Brain Res. 346 1985 141 145
32. M. Markota, J. Sin, H. Pantazopoulos, R. Jonilionis, and S. Berretta Reduced dopamine transporter expression in the amygdala of subjects diagnosed with schizophrenia Schizophr. Bull. 40 2014 984 991
33. P.N. McCormick, S. Kapur, A. Graff-Guerrero, R. Raymond, J.N. Nobrega, and A.A. Wilson The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro Neuropsychopharmacology 35 2010 1826 1835
34. A.N. Mead, H.S. Crombag, and B.A. Rocha Sensitization of psychomotor stimulation and conditioned reward in mice: differential modulation by contextual learning Neuropsychopharmacology 29 2004 249 258
35. H.Y. Meltzer, S. Matsubara, and J.C. Lee The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs Psychopharmacol. Bull. 25 1989 390 392
36. P. Muller, and P. Seeman Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors Life Sci. 21 1977 1751 1758
37. L.E. O'Dell, A.N. Sussman, K.L. Meyer, and J.L. Neisewander Behavioral effects of psychomotor stimulant infusions into amygdaloid nuclei Neuropsychopharmacology 20 1999 591 602
38. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1986 Academic New York
39. D.O. Perkins Adherence to antipsychotic medications J. Clin. Psychiatry 60 Suppl. 21 1999 25 30
40. R.C. Pierce, J.K. Rowlett, M.T. Bardo, and G.V. Rebec Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding Neuroscience 45 1991 373 378
41. L. Rauser, J.E. Savage, H.Y. Meltzer, and B.L. Roth Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor J. Pharmacol. Exp. Ther. 299 2001 83 89
42. G.P. Reynolds Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia Nature 305 1983 527 529
43. T.W. Robbins The acquisition of responding with conditioned reinforcement: effects of pipradrol, methylphenidate, d-amphetamine, and nomifensine Psychopharmacology (Berl) 58 1978 79 87
44. T.W. Robbins, and B.J. Everitt Functional studies of the central catecholamines Int. Rev. Neurobiol. 23 1982 303 365
45. A.N. Samaha Can antipsychotic treatment contribute to drug addiction in schizophrenia? Prog. Neuropsychopharmacol. Biol. Psychiatry 52 2014 9 16
46. A.N. Samaha, G.E. Reckless, P. Seeman, M. Diwan, J.N. Nobrega, and S. Kapur Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery Biol. Psychiatry 64 2008 145 152
47. A.N. Samaha, P. Seeman, J. Stewart, H. Rajabi, and S. Kapur "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time J. Neurosci. 27 2007 2979 2986
48. F. Schlagenhauf, G. Juckel, M. Koslowski, T. Kahnt, B. Knutson, T. Dembler, T. Kienast, J. Gallinat, J. Wrase, and A. Heinz Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine Psychopharmacology (Berl) 196 2008 673 684
49. R.E. See, and M.A. Chapman Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats Eur. J. Pharmacol. 263 1994 269 276
50. P. Seeman, R. Corbett, and H.H. Van Tol Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors Neuropsychopharmacology 16 1997 93 110 Discussion 111-135
51. R.C. Smith, and J.M. Davis Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine Life Sci. 19 1976 725 731
52. F. Tascedda, J.M. Blom, N. Brunello, K. Zolin, M. Gennarelli, A. Colzi, D. Bravi, S. Carra, G. Racagni, and M.A. Riva Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats Biol. Psychiatry 50 2001 117 122
53. J. Tauscher, C. Jones, G. Remington, R.B. Zipursky, and S. Kapur Significant dissociation of brain and plasma kinetics with antipsychotics Mol. Psychiatry 7 2002 317 321
54. J.R. Taylor, and T.W. Robbins Enhanced behavioural control by conditioned reinforcers following microinjections of d-amphetamine into the nucleus accumbens Psychopharmacology (Berl) 84 1984 405 412
55. J.R. Taylor, and T.W. Robbins 6-Hydroxydopamine lesions of the nucleus accumbens, but not of the caudate nucleus, attenuate enhanced responding with reward-related stimuli produced by intra-accumbens d-amphetamine Psychopharmacology (Berl) 90 1986 390 397
56. G.D. Tollefson, M.A. Dellva, C.A. Mattler, J.M. Kane, D.A. Wirshing, and B.J. Kinon Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group J. Clin. Psychopharmacol. 19 1999 435 443
57. E.M. van der Zwaal, M.C. Luijendijk, R.A. Adan, and S.E. la Fleur Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution Eur. J. Pharmacol. 585 2008 130 136
58. M.L. Wadenberg, S. Kapur, A. Soliman, C. Jones, and F. Vaccarino Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats Psychopharmacology (Berl) 150 2000 422 429
59. M.L. Wadenberg, A. Soliman, S.C. VanderSpek, and S. Kapur Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects Neuropsychopharmacology 25 2001 633 641
60. B.K. Yamamoto, and M.A. Cooperman Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations J Neurosci. 14 1994 4159 4166
61. J.Y. Zhang, D.M. Kowal, S.P. Nawoschik, Z. Lou, and J. Dunlop Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms Biochem. Pharmacol. 71 2006 521 529